Evotec SE (EVTCY.PK,EVOTF.PK) and Novo Nordisk (NVO) have agreed on a strategic collaboration on the discovery and development of new therapeutics for patients with chronic kidney disease. Novo Nordisk will be responsible for the clinical development and commercialisation of the products. Evotec will receive an undisclosed upfront payment, research funding and milestone potential of more than 150 million euros per product as well as tiered royalties on net sales.
Under the collaboration, Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets of thousands ofchronic kidney disease patients.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.